Integra LifeSciences
IART
223 hedge funds and large institutions have $1.57B invested in Integra LifeSciences in 2024 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 78 increasing their positions, 69 reducing their positions, and 40 closing their positions.
3,790% more call options, than puts
Call options by funds: $13.4M | Put options by funds: $345K
26% more capital invested
Capital invested by funds: $1.24B → $1.57B (+$329M)
13% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 69
3% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 40
0.82% less ownership
Funds ownership: 90.69% → 89.87% (-0.82%)
1% less funds holding
Funds holding: 225 → 223 (-2)
Top Buyers
Top Sellers
IART Hedge Fund Activity: Q4 2024 in Review
223 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q4 2024, worth a combined $1.57B — up 26% from $1.24B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new IART positions and 40 closed out — a net gain of 1 holder — while 78 added to existing stakes and 69 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $50.8M. The largest seller was Sachem Head Capital Management, exiting entirely with an estimated $44.2M sold.
- 223 institutional investors held Integra LifeSciences (IART) as of Q4 2024, down from 225 in Q3 2024.
- Funds reported $1.57B of Integra LifeSciences stock for Q4 2024, up 26% quarter-over-quarter.
- 41 funds opened new Integra LifeSciences positions in Q4 2024 and 40 closed out, a net change of +1 holder.
- The largest Integra LifeSciences buyer in Q4 2024 was Rubric Capital Management (New York), an estimated $50.8M added.
- The largest Integra LifeSciences seller in Q4 2024 was Sachem Head Capital Management, an estimated $44.2M sold.
Based on aggregated 13F filings for Q4 2024.